Q-omics provides the consensus-scored POLR1E profile across patient tissues and cancer cell-line models. POLR1E expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLR1E is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, POLR1E protein abundance shows 26,618 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where POLR1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR1E survival associations across molecular data types. POLR1E RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR1E RNA expression–survival associations across cancer types. High POLR1E expression shows unfavorable associations in ACC, KICH, KIRP and BLCA, but favorable associations in KIRC and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLR1E RNA expression.
This table summarizes POLR1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLR1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR1E shows lower tumor expression in UCEC and BRCA and higher tumor expression in COAD, KIRC, KIRP and HNSC. The COAD box plot shows higher POLR1E RNA expression in tumor versus normal tissue (log2 FC = +1.210, t-test p < 0.001).
This table shows molecular features associated with POLR1E in patient tissues and cancer cell lines. In patient samples, POLR1E shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
